BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ARTES Biotechnology Issued New Patent in Australia for VLP Technology


4/22/2013 10:38:33 AM

Langenfeld, April 19th, 2013. ARTES Biotechnology specialized in microbial cell line and process development as well as in technology transfer for pharmaceutical industry is pleased to announce the issuance of a new patent for their VLP platform. The patent will further strengthen the Metavax® platform of the company. In combination with the expression platform Hansenula Metavax® is a unique tool for the development of affordable, safe and effective vaccines. “Our intellectual property strategy is to provide multiple layers of protection for our technology platform portfolio. We believe that this new patent will have additional reinforcement to our existing patent estate and for our service we offer clients for vaccine development,” said Dr. Melanie Piontek, Business Development Director of ARTES.

ARTES Biotechnology GmbH – www.artes-biotechnology.com

ARTES is a Germany-based biotechnology company specialized in recombinant protein production and process development from microbial expression systems. ARTES offers generation of optimized production cell lines in proprietary yeast expression systems based on Hansenula polymorpha. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld. The company focuses on contract R&D for red and white biotechnology products.

Contact:

ARTES Biotechnology GmbH

Dr. Melanie Piontek

Business Development Director

+49 (0)2173 275870

piontek@artes-biotechnology.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES